Adjunct Digital Interventions Improve Opioid-Based Pain Management: Impact of Virtual Reality and Mobile Applications on Patient-Centered Pharmacy Care.

Autor:	Giravi HY; University of Utah College of Pharmacy, Salt Lake City, UT, United States., Biskupiak Z; Department of Medicinal Chemistry, L.S. Skaggs College of Pharmacy, University of Utah, Salt Lake City, UT, United States., Tyler LS; Department of Pharmacotherapy, L.S. Skaggs College of Pharmacy, University of Utah, Salt Lake City, UT, United States., Bulaj G; Department of Medicinal Chemistry, L.S. Skaggs College of Pharmacy, University of Utah, Salt Lake City, UT, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in digital health [Front Digit Health] 2022 Jun 13; Vol. 4, pp. 884047. Date of Electronic Publication: 2022 Jun 13 (Print Publication: 2022).
DOI:	10.3389/fdgth.2022.884047
Abstrakt:	Digital therapeutics (DTx, mobile medical apps, software as a medical device) are rapidly emerging as clinically effective treatments for diverse chronic diseases. For example, the Food and Drug Administration (FDA) has recently authorized a prescription virtual reality (VR) app for treatment of moderate to severe low back pain. The FDA has also approved an adjunct digital therapy in conjunction with buprenorphine for opioid use disorder, further illustrating opportunities to integrate digital therapeutics with pharmacotherapies. There are ongoing needs to disseminate knowledge about advances in digital interventions among health care professionals, policymakers, and the public at large. This mini-review summarizes accumulating clinical evidence of digital interventions delivered via virtual reality and mobile apps to improve opioid-based analgesia. We identified relevant randomized controlled trials (RCTs) using Embase and PubMed databases which reported pain scores with a validated pain scale (e.g., visual analog scales, graphic rating scale, numeric rating scale) and use of a digital intervention in conjunction with opiates. Among identified RCTs, the majority of studies reported improved pain scores in the digital intervention group, as compared to "treatment as usual" group. Our work suggests that VR and mobile apps can be used as adjunct digital therapies for pain management. We discuss these findings in the context of how digital health technologies can transform patient-centered pharmacy care. Competing Interests: GB is a founder and owner of OMNI Self-care, LLC, a health promotion company creating digital content for disease self-management and is a co-inventor on two issued US patents 9,569,562 and 9,747,423 “Disease Therapy Game Technology” and patent-pending application “Multimodal Platform for Treating Epilepsy”. These patents are related to digital health technologies, and are owned by the University of Utah. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Giravi, Biskupiak, Tyler and Bulaj.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu